2026 Recipients
Kevin Vargo
Kevin Vargo | Chemical Engineering
Sr. Director, Johnson and Johnson
Kevin Vargo has helped transform scientific innovation into medicines that improve and extend patients’ lives. Across a career spanning biologics discovery, development, manufacturing, and regulatory strategy, he has built and led multidisciplinary teams that advance promising scientific ideas into therapies capable of reaching patients worldwide.
His leadership has contributed to the development and commercialization of TREMFYA®, RYBREVANT®, TECVAYLI®, and TALVEY®, providing important treatment options for people living with immune-mediated diseases and difficult-to-treat cancers. As Global Chemistry, Manufacturing and Controls Lead for TALVEY®, Kevin guided a broad international team through late-stage development, regulatory submission, and approval, helping deliver a novel therapy for patients with multiple myeloma.
Kevin’s impact extends across more than 50 pipeline programs, multiple therapeutic areas, and a wide range of biologic technologies. He is also an inventor on eight patents and an author of more than 10 peer-reviewed publications. Today, as Head of Biologics Discovery Process Research at Johnson & Johnson Innovative Medicine, he leads an organization that connects discovery and development, strengthening the path from breakthrough science to manufacturable medicines.
Beyond individual products and programs, Kevin has created lasting impact by developing scientific talent, building collaborative organizations, and advancing capabilities that enable future generations of biologic medicines. His career reflects a sustained commitment to scientific excellence, purposeful leadership, and better outcomes for patients.